Pharmaceuticals
Lynk Pharmaceuticals Announces Clinical Approval in China for Its Class I New Drug LNK01004
HANGZHOU, China, April 22, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that its Class I innovative drug LNK01004, has been approved by National Medical Products Administration (NMPA) for c...
2022-04-22 08:00
4129
Telix Further Strengthens European Distribution Network for Illuccix
MELBOURNE, Australia and LIÈGE, Belgium, April 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces agreements with Sociedade Avanço, Unipessoal, LDA (Avanço) and THP Medical Products Vertriebs GmbH (THP) for the distribution of Telix's prostate ca...
2022-04-22 07:10
4289
Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets
* Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics * Transaction includes worldwide exclusive rights for development and commercialization in all fields of use NEW YORK, April 21, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company...
2022-04-21 22:39
4825
Transcenta Successfully Passed the Audit of EU Qualified Person for the Manufacturing of TST001
SUZHOU, China, April 21, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that HJB (Hangzhou) ...
2022-04-21 19:20
3917
Wallaby Acquires German Neurovascular Leader Phenox to Accelerate Global Expansion
LAGUNA HILLS, Calif. and SHANGHAI and BOCHUM, Germany, April 21, 2022 /PRNewswire/ -- Wallaby Medical ("Wallaby" or the "Company"), a global innovative medical technology company focused on developing and commercializing neurovascular interventional products for treating stroke, today announced t...
2022-04-21 17:00
1796
Nippon Express Obtains IATA CEIV Pharma Certification for Temperature-controlled Facility at Kansai International Airport
TOKYO, April, 21, 2022 /PRNewswire/ -- Nippon Express Co., Ltd. (hereinafter "Nippon Express"), a group company of Nippon Express Holdings, Inc., has obtained IATA CEIV Pharma (*) pharmaceutical transport quality certification, effectiveApril 5, for its temperature-controlled facility "NX-PHARMA ...
2022-04-21 14:00
2898
JW Therapeutics Announces IND Approval for the Clinical Trial of Carteyva® in Pediatric and Young Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
SHANGHAI, April 20, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced the Investigational New Drug (IND) clearance from the National Medical Products ...
2022-04-20 18:30
5472
Samsung Biologics completes full acquisition of Samsung Bioepis
* Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary * First payment completed funded through paid-in capital * Accelerated growth expected in biosimilars and future novel therapeutics R&D INCHEON,South Korea, April 20, 2022 /PRNewswire/ -- Samsung Biologi...
2022-04-20 14:45
2801
SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
COPENHAGEN, Denmark, April 20, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome gene therapy biotechnology company, today announced dosing of the first human subjects in its phase 1 clinical trial with SNIPR001, an orally administered CRISPR-based therapeutic. The purpose of...
2022-04-20 14:04
2159
FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies
CHENGDU, China, April 19, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that the U.S. Food and Drug Administration (FDA) granted CMG901 Fast Track Designation as monotherapy for the treatment of unresectable or metastatic gastric and gastroesophageal junction cancer which have relap...
2022-04-20 10:27
2342
ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S.
SHENZHEN, China, April 19, 2022 /PRNewswire/ -- ImmVira announced that, company has reached a cooperation agreement with Roche to establish clinical research partnership recently, to conduct clinicalstudies in the U.S. on the combination therapy of ImmVira's MVR-T3011 IT and Roche's MEK inhibitor...
2022-04-20 08:00
2274
Gastroenterology: NTC submits marketing authorisation application for KLEERKOL® in EU
MILAN, April 19, 2022 /PRNewswire/ -- NTC Srl, R&D driven pharmaceutical company with headquarters inItaly announces the submission of the marketing authorisation application through the European Decentralised Procedure (DCP) for its development product NTC015 (Kleerkol®) for bowel preparation fo...
2022-04-19 18:00
3175
Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19
- In antiviral cellular assays, antiviral potency (EC90) of ASC11 is 31-fold of that of Nirmatrelvir, 120-fold of that of S-217622, 16-fold of that of PBI-0451 and 7-fold of that of EDP-235. - ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3CLpro, with global intel...
2022-04-19 16:50
3837
Mediscience Espoir Inc. Looking for OEM Customers, Technical Business Partners and Sales Agents for Oxygen Clathrate Hydrates and Oxygen Solutions
KAWASAKI, Japan, April 19, 2022 /PRNewswire/ -- Mediscience Espoir Inc. announced onApril 19 that it is looking for U.S. partners for oxygen clathrate hydrates and oxygen solutions based on its proprietary technology. The company obtained "Substance Patent" in the United States (US 10,913,037 B2)...
2022-04-19 14:00
2123
Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day
NANJING, China, April 19, 2022 /PRNewswire/ -- On April 15, 2022, Simcere Pharmaceutical (2096.HK), an innovation and R&D driven pharmaceutical company in China held its first R&D day for international investors, during which the executive leaders revealed Simere's R&D strategy, and gave an update...
2022-04-19 10:28
2699
GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate
SUZHOU, China, April 18, 2022 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has signed an agreement with a Korean biotech company, Aimed Bio Inc., to co-develop a First-in-Class therapeutic an...
2022-04-19 09:00
2187
Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases
* New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine Congress * Several abstracts and presentations slated to highlight updates on NVX-CoV2373, Novavax' COVID-19 vaccine GAITHERSBURG, Md., April 18, 2022 /PRNewswire/ -- Novavax...
2022-04-18 22:13
4793
WHO report highlights the role of Traditional Chinese Medicine in the treatment of COVID-19
BEIJING, April 18, 2022 /PRNewswire/ -- A news report by haiwainet.cn: On March 31, World Health Organization released the meeting report of "WHO Expert Meeting on Evaluation of Traditional Chinese Medicine (TCM) in the Treatment of COVID-19" on its official website. The report acknowledged that ...
2022-04-18 15:18
2594
Illumina Singapore Jumps the Ranks to Earn Two Significant Spots in Singapore's Best Employers Award
The Annual Singapore's Best Employers survey is sponsored by The Straits Times and marketing firm, Statista. SINGAPORE, April 18, 2022 /PRNewswire/ -- Illumina Singapore, subsidiary of Illumina Inc (NASDAQ: ILMN) was honoured today to be ranked #17 overall and #1 in Healthcare Equipment & Servic...
2022-04-18 12:00
3930
Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy
SHANGHAI, April 14, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative pharmaceutical company specializing in the treatment of genitourinary cancers and related major diseases, announced its 2021 annual report today. The company is currently making steady progress in mu...
2022-04-14 22:49
3603
Week's Top Stories
Most Reposted
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00KC Global Media announces new travel series "AXN Ultimate Challenge: Sarawak"
[Picked up by 291 media titles]
2026-07-30 09:12
ADA acquires Algonomy, strengthening its intelligent growth platform for a fully agentic experience
[Picked up by 290 media titles]
2026-07-30 15:30
Articura Launches a New Chapter for Sovereign Healthcare AI in Indonesia
[Picked up by 290 media titles]
2026-07-27 19:02
